Improvement of Disability and QOL by Triptans in Migraine : Assessment by MIDAS and HIT-6 scores

  • Otsuka Noriko
    The Third Department of Internal Medicine (Neurology), Faculty of Clinical Medicine, Kitasato University Graduate School of Medical Science
  • Sakai Fumihiko
    The Third Department of Internal Medicine (Neurology), Kitasato University School of Medicine
  • Iigaya Miho
    The Third Department of Internal Medicine (Neurology), Kitasato University School of Medicine
  • Igarashi Hisaka
    The Third Department of Internal Medicine (Neurology), Kitasato University School of Medicine
  • Shirataka Masuo
    The Department of Health Science, Faculty of General Studies, Kitasato University

Bibliographic Information

Other Title
  • トリプタンによる片頭痛支障度・QOL改善評価 : MIDAS・HIT-6スコアを用いて

Search this article

Description

Migraine affects 8.4% of the general population in Japan and exerts a significant impact and impairs the quality of life (QOL) of the patients with migraine. Triptans, 5-HTIB/ID receptor agonists, were approved in Japan in 2001, as a new type of drug for the acute treatment of migraine. We studied to know whether Triptans improved the level of disability and QOL using two assessment scores. The MIDAS (Migraine Disability Assessment) questionnaire and the HIT-6 (Headache Impact Test-6) questionnaire are valid tools for evaluating headache-related disability, assessment of pain intensity, headache frequency, lost work time and reduced productivity. In this study, the disability level was measured in 62 patients with migraine using both MIDAS and HIT-6 before and after the administration of oral Triptan. In the patients before and after the administration of Triptan, it was confirmed that MIDAS scores decreased from 27.2 days to 15.5 days, and HIT-6 scores decreased from 65.5 to 59.7 after the treatment with Triptan. The results showed the usefulness of Triptan for acute treatment of migraine. Both MIDAS and HIT-6 were considered to be useful for the assessment of treatment in the primary care of headache. The use of these impact tools will improve communication between physicians and their patients and promote an individualized treatment plan such as "tailor-made medicine".

Journal

  • Kitasato medicine

    Kitasato medicine 33 (2), 149-157, 2003-04-30

    Kitasato University

Keywords

Details 詳細情報について

Report a problem

Back to top